| Original language | English (US) |
|---|---|
| Pages (from-to) | 499-502 |
| Number of pages | 4 |
| Journal | The Lancet |
| Volume | 393 |
| Issue number | 10171 |
| DOIs |
|
| State | Published - Feb 9 2019 |
ASJC Scopus subject areas
- General Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: The Lancet, Vol. 393, No. 10171, 09.02.2019, p. 499-502.
Research output: Contribution to journal › Comment/debate › peer-review
}
TY - JOUR
T1 - From #MeToo to #TimesUp in health care
T2 - can a culture of accountability end inequity and harassment?
AU - Choo, Esther K.
AU - Byington, Carrie L.
AU - Johnson, Niva Lubin
AU - Jagsi, Reshma
N1 - Funding Information: EKC is: co-founder of Equity Quotient, a company that evaluates culture in health-care companies; President of the Gender Equity Research Foundation, a non-profit organisation that raises funds for research on equity in health care; and senior adviser to FeminEM.org , which supports the careers of women in medicine. EKC has received grant funding from the National Institutes for Health and the Insurance Institute of Highway Safety unrelated to this work. CLB has intellectual property in and receives royalties from BioFire Diagnostics; and has received grant funding from the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the National Institutes for Health, and Blue Cross Blue Shield of Texas unrelated to this work. RJ has stock options as compensation for her advisory board role in Equity Quotient; and has received personal fees from Amgen and Vizient and grants for unrelated work from the National Institutes of Health, the Doris Duke Foundation, the Greenwall Foundation, the Komen Foundation, and Blue Cross Blue Shield of Michigan for the Michigan Radiation Oncology Quality Consortium. N-LJ declares no competing interests.
PY - 2019/2/9
Y1 - 2019/2/9
UR - http://www.scopus.com/inward/record.url?scp=85061085111&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061085111&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(19)30251-X
DO - 10.1016/S0140-6736(19)30251-X
M3 - Comment/debate
C2 - 30739670
AN - SCOPUS:85061085111
SN - 0140-6736
VL - 393
SP - 499
EP - 502
JO - The Lancet
JF - The Lancet
IS - 10171
ER -